
New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.
A comparison of 2024 and 2025 bio/pharma employment survey results indicates that industry professionals face eroding security, polarized satisfaction, and rising attrition risk.
This article was originally published by





